Rosa & Co. Announces Multi-Year, World-Wide PhysioPD™ Research Agreement with Sanofi
SAN CARLOS, Calif., May 28, 2015 /PRNewswire/ -- Rosa & Co. LLC, a drug development advisory firm with expertise in drug-disease modeling and simulation, today announced the initiation of a multi-year Research Agreement with Sanofi Global R&D to provide Rosa's market-leading PhysioPD services to worldwide Sanofi affiliates.
Logo - http://photos.prnewswire.com/prnh/20150527/218871LOGO
The collaboration with Rosa provides Sanofi a competitive research and development advantage across all therapeutic areas with a more systematic and long-term relationship with Rosa & Co. The agreement is designed to provide greater access to the extensive depth and breadth of Rosa's expertise and foster enhanced adoption of the PhysioPD™ Platform development approach throughout Sanofi's entire R&D pipeline.
Rosa's agreement with Sanofi further extends Rosa's presence as the global market leader in the Quantitative Systems Pharmacology field. It also reinforces the value PhysioPD™ Research Platforms deliver through greater scientific insight and more informed drug discovery and development decisions.
"We are honored that our Research Agreement with Sanofi is the first that we can announce publicly. It demonstrates their commitment to be a market leader in the use of PhysioPD to achieve the scientific and drug development benefits delivered by PhysioPD research. It also further demonstrates the significant value PhysioPD research can deliver to R&D portfolios.
- Dr. Ron Beaver, Founder, Chairman, and CEO, Rosa & Co. LLC
About Rosa
Rosa supports clients with their critical decisions – from preclinical through clinical development – with the creation and use of mathematical PhysioPD™ Research Platforms. These Platforms are customized to allow clients to simulate normal and disease physiology, drug action, patient variability, and trial outcomes and efficiently answer the full spectrum of questions related to targets, mechanisms, and outcomes. Rosa's clients participate in Platform creation and biological simulation research, and retain the Platforms to perform additional program research. Rosa's staff has unparalleled professional experience applying biological modeling and simulation research to optimize drug development and has completed hundreds of engagements with clients in virtually all therapeutic areas. Rosa is unique in its breadth and depth of disease area expertise in oncology, immuno-oncology, inflammation, autoimmunity, metabolism, cardiovascular, dermatology, central nervous system, antibacterial, and antiviral biology. For more information, visit http://www.rosaandco.com/news.html
Rosa and the Rosa logo are registered trademarks of Rosa & Co. LLC.
Media Contact:
Stephanie Sherman
425-591-5738
Email
SOURCE Rosa & Co.
Related Links
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article